Abstract
The Epidermal growth factor receptor (EGFR) family plays an important role in carcinogenesis. CIMAher® (Nimotuzumab), is a humanized monoclonal antibody, which recognizes EGFR with high affinity. The aim of this work was to perform the direct labeling of Nimotuzumab with [99mTc(CO)3(H2O)3]+ as precursor and to evaluate its labeling conditions, in vitro and in vivo stability and biodistrution in normal C57 BL/6J mice. 99mTc(CO3)-Nimotuzumab labeling yields were up to 90%. More than 90% of the complex remained intact after 24 h of incubation with L-Histidine (1/300 molar ratio). Biodistribution studies in normal mice were also performed. Inmunoreactivity was confirmed by cell binding assays with A431cells. These results encourage the evaluation of the potential role of 99mTc(CO3)-Nimotuzumab as a novel tumor-avid radiotracer for targeting in vivo EGFR expression.
Keywords: 99m-Technetium, Nimotuzumab, EGFR, tricarbonyl, Epidermal growth factor receptor
Current Radiopharmaceuticals
Title: Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies
Volume: 5 Issue: 1
Author(s): Maria Fernanda Garcia, Ximena Camacho, Victoria Calzada, Marcelo Fernandez, Williams Porcal, Omar Alonso, Juan Pablo Gambini and Pablo Cabral
Affiliation:
Keywords: 99m-Technetium, Nimotuzumab, EGFR, tricarbonyl, Epidermal growth factor receptor
Abstract: The Epidermal growth factor receptor (EGFR) family plays an important role in carcinogenesis. CIMAher® (Nimotuzumab), is a humanized monoclonal antibody, which recognizes EGFR with high affinity. The aim of this work was to perform the direct labeling of Nimotuzumab with [99mTc(CO)3(H2O)3]+ as precursor and to evaluate its labeling conditions, in vitro and in vivo stability and biodistrution in normal C57 BL/6J mice. 99mTc(CO3)-Nimotuzumab labeling yields were up to 90%. More than 90% of the complex remained intact after 24 h of incubation with L-Histidine (1/300 molar ratio). Biodistribution studies in normal mice were also performed. Inmunoreactivity was confirmed by cell binding assays with A431cells. These results encourage the evaluation of the potential role of 99mTc(CO3)-Nimotuzumab as a novel tumor-avid radiotracer for targeting in vivo EGFR expression.
Export Options
About this article
Cite this article as:
Fernanda Garcia Maria, Camacho Ximena, Calzada Victoria, Fernandez Marcelo, Porcal Williams, Alonso Omar, Pablo Gambini Juan and Cabral Pablo, Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies, Current Radiopharmaceuticals 2012; 5 (1) . https://dx.doi.org/10.2174/1874471011205010059
DOI https://dx.doi.org/10.2174/1874471011205010059 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of AHSA1 as a Potential Therapeutic Target for Breast
Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine Synthesis and Evaluation of <sup>198</sup>Au/PAMAM-MPEG-FA against Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Radiolabelled Oligonucleotides for Imaging of Gene Expression with PET
Current Medicinal Chemistry Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies
Current Topics in Medicinal Chemistry Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Preclinical Molecular Imaging of the Translocator Protein (TSPO) in a Metastases Model Based on Breast Cancer Xenografts Propagated in the Murine Brain
Current Molecular Medicine Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery